Tag Archives: Collaborative Drug Discovery Programmes

Repurposing of Existing Drugs to Prevent Dementia? (BBC News / Science Advances /Alzheimer’s Research UK)

Posted on February 13, 2016 by Dementia and Elderly Care News

Summary A number of drugs, already approved as safe for the treatment of other conditions, and which could help protect against Alzheimer’s Disease, are said to have been detected and short-listed for further investigation. Full Text Link Reference Alzheimer’s preventative … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Research UK, Animal Studies, BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Ab42 Fibril Formation, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta Protein, Amyloid Cascade Hypothesis, Amyloid Hypothesis, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β Protein, Anti-Amyloid Therapies, ARUK: Alzheimer’s Research UK, ß-amyloid, BBC Health News, Behind the Headlines, Beta-Amyloid, Bexarotene (Elevated Triglycerides), Bexarotene (Targretin), Center for Molecular Protein Science: Lund University, Cleveland Clinic Lou Ruvo Center for Brain Health, Collaborative Drug Discovery Programmes, Conversion to Dementia From Prodromal Disease, Critical Appraisals, Department of Biochemistry and Structural Biology: Lund University, Department of Chemistry: University of Cambridge, Department of Psychology: University of Nevada, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, European Research Institute for the Biology of Aging (Groningen), Fibrillar Deposits (Alzheimer's Disease), Fibrils, β-Amyloid 1-42 (Aβ42), Lund University (Sweden), Microscopic Worms, Netherlands, Neurofibrillary Tangles (NFTs), Neurological Research, Neurostatin (Hypothetical Construct), Off-Label Drug Repurposing Trials, Off-Licence Drugs, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prodromal Alzheimer's Disease, Protein Aggregation, Repurposing of Drugs, RXR Agonists, Science Advances (Journal), Statins for the Brain (Hypothetical Construct), Sweden, University Medical Centre Groningen, University of Cambridge, University of Groningen, University of Nevada, USA, Worms: C. elegans | Leave a comment

Big Data Portal for Alzheimer’s Dementia Drug Discovery (NIH / Synapse AMP-AD)

Posted on March 8, 2015 by Dementia and Elderly Care News

Summary The National Institutes of Health (NIH) in the USA has opened a public-private partnership online resource to facilitate neurodegenerative research and drug development. The launch of the Alzheimer’s Big Data Portal provides an open-source “public knowledge portal” for the … Continue reading →

Posted in Charitable Bodies, For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights | Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Accelerating Alzheimer's Research and Drug Development, Accelerating Medicine Partnership for Alzheimer's Disease (NIA-AMP AD) Target Discovery and Preclinical Validation Project, Accelerating Medicines Partnership (AMP), Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD), Alfred P. Sloan Foundation, Alzheimer’s Disease Biomarkers, Alzheimer’s Disease Cooperative Study, Alzheimer’s Disease Neuroimaging Initiative (ADNI), AMP-AD Program, Big Data, Big Data Portal for Alzheimer’s Dementia Drug Discovery, Big Pharma, Biomarkers, Biopharmaceutical Companies, Broad Institute of MIT and Harvard, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Cross-Sector Partnerships, Dementia Research, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Emory University, Foundation for the NIH (FNIH), Genetic Research, Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Global Open Data Initiative, Human Epigenome Atlas, Icahn School of Medicine at Mount Sinai, Institute for Systems Biology (Seattle), International Alzheimer's Disease Research Portfolio (IADRP), International Collaborations, International Organisations, International Programmes, Market Failure (Dementia Research and Drug Development), Mayo Clinic in Jacksonville, Medical Research, Multidisciplinary Research Teams, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, NIA Genetics of Alzheimer’s Data Storage Site (NIAGADS), NIH Big Data to Knowledge (BD2K) Initiative, NIH Network for Excellence in Neuroscience Clinical Trials, Non-Profit Collaborations, Novel Targets in Neurodegeneration, Open Data, Open Data and Big Data, Open Data in Health and Social Care, Open Data Learning Capacity and Culture, Open Data: Unlocking Innovation, Open Source Solutions, Pharmaceutical Industry, Pharmacological Research, Potential of Open Data in Health and Social Care, Pre-Competitive Collaboration, Precision Medicine Initiative, Preclinical Biomarkers in Alzheimer's Disease, Public-Private Partnership (PPP), Public-Private Partnerships, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Roadmap Epigenomics Project, Rush University Medical Center: Chicago, Sage Bionetworks, Synapse, Synapse Access and Compliance Team, Target Discovery and Preclinical Validation, Technology Transfer, Temporal Evolution of Alzheimer’s Disease Biomarkers, Therapeutic Target(s): Identification, Translational Research, Transparency and Open Data, United States, University of California, University of Florida, US National Institute of Aging, US National Institutes of Health (NIH), USA | Leave a comment

UK-Based Drug Discovery Alliance (BBC News / Alzheimer’s Research UK)

Posted on February 16, 2015 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK has announced the launch of the Drug Discovery Alliance, a £30 million network of research centres working collaboratively on research to discover potential cures, or at least disease modifying treatments, for Alzheimer’s Disease and other forms … Continue reading →

Global Clinical Trials Fund: GCTF (Alzheimer’s Research UK)

Posted on December 22, 2014 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK has launched the Global Clinical Trials Fund (GCTF) to help finance trials which aim to translate discoveries in the lab into clinical treatments for the 830,000 people living with dementia in the UK. The GCTF aims … Continue reading →

Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Models of Dementia Care, National, Non-Pharmacological Treatments, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest | Tagged Alzheimer’s Research UK Drug Discovery Institute, Clinical Research Networks, Clinical Trials, Clinical Trials (Phase I Through Phase III), Clinical Trials and Treatment Assessments, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Commissioning Research, Dementia Consortium, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Disease Modifying Treatment by 2025 (Aim), Drug Discovery Institute, Drug Discovery Institutes, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, GCTF: Global Clinical Trials Fund, Global Action Against Dementia, Global Clinical Trials Fund (GCTF), International Collaborations, International Organisations, International Programmes, Intervention Trials, Medical Research, Multidisciplinary Research Teams, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, New Drug Applications (NDAs), Non-Drug Intervention Trials, Novel Targets in Neurodegeneration, Pharmaceutical Industry, Pharmacological Research, Pharmacological Treatments, Pharmacotherapy, Pre-Competitive Collaboration, Research Commitment, Research Consortia, Research Culture, Research Programmes, Technology Transfer, Translational Research | Leave a comment

Dementia Consortium (Alzheimer’s Research UK)

Posted on July 15, 2014 by Dementia and Elderly Care News

Summary The Dementia Consortium has been established to fund academic dementia research experts from the UK and overseas in their efforts to develop early research findings concerning Alzheimer’s Disease, and other forms of dementia, into validated drug targets. “The Dementia … Continue reading →

Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights, UK | Tagged ARUK: Alzheimer’s Research UK, Big Pharma, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Dementia Consortium, Dementia Research, Dementia Research Priorities, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Eisai Ltd, Eli Lilly, Fast-Tracking New Potential Treatments, Justin Bryans: MRC Technology, Lilly, MRC Technology, MRC Technology (Independent Life Science Technology Transfer Charity), MRCT: MRC Technology, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, New Drug Applications (NDAs), Novel Targets in Neurodegeneration, Pharmaceutical Industry, Pharmacological Research, Pharmacological Treatments, Pharmacotherapy, Pre-Competitive Collaboration, Technology Transfer, Translational Research | Leave a comment

Tag Archives: Collaborative Drug Discovery Programmes

Repurposing of Existing Drugs to Prevent Dementia? (BBC News / Science Advances /Alzheimer’s Research UK)

UK-Based Drug Discovery Alliance (BBC News / Alzheimer’s Research UK)

Global Clinical Trials Fund: GCTF (Alzheimer’s Research UK)

Dementia Consortium (Alzheimer’s Research UK)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites